New chairman for Egenix
December 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing egenix, lionel goldfrank
Lionel Goldfrank has been elected to sit on the board of the US-based biotech firm Egenix. Goldfrank is to succeed Donald …
Cubist boosts antibiotics market presence
December 22, 2014Sales and Marketing Antibiotics, Zerbaxa, antimicrobial resistance, bacteria, cubist, infections, infectious diseases
Cubist has followed-up its successful European approval for a new antibiotic by winning an endorsement by the US FDA. The …
Lilly to market stomach cancer drug in Europe
December 22, 2014Sales and Marketing Eli Lilly, Europe, FDA, US, cyramza, ramucirumab, stomach cancer
Eli Lilly has been granted permission by the European Commission to market Cyramza in Europe. Lilly’s Cyramza (ramucirumab) is the …
Abbvie Hep C drug gains FDA approval
December 22, 2014Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C
Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …
Chiesi gets first-ever European stem cell nod
December 19, 2014Sales and Marketing Chiese, Chiesi, EMA, Holoclar, LSCD, MHRA, Stem cells, orexigen
Chiesi has received the first approval for an advanced therapy medicinal product containing stem cells for use in Europe. The …
Visions for the future: FT pharma and biotech event
December 19, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, ABPI, Deloitte, Medidata, Whitehead, financial ties, freeman, ft pharma
The FT Global Pharmaceutical and Biotechnology Conference held in London recently asked: “What will the life science company of the …
Merck acquires Swiss firm OncoEthix
December 19, 2014Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab
Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …
Roche dealt with two late-stage blows
December 19, 2014Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine
Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …
GSK shingles vaccine on form
December 19, 2014Sales and Marketing GSK, HZ/su, Merck, Vaccine, Zostavax, shingles
GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary …
NHS not au fait with mobile-savvy patients
December 19, 2014Medical Communications, Sales and Marketing NHS, app, digital, health, mobile, smartphones, wearables
The NHS is failing to keep up with its digital generation of patients, a recent study has found. Despite a …
Takeda takes senior head from Sanofi
December 19, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Takeda, andrew plump
Dr Andrew Plump will be joining Takeda in February from Sanofi to lead its global R&D operations as chief medical …
New Lyrica formulation effective in trials
December 19, 2014Sales and Marketing HIV, Lyrica, Pfizer, pain, pregabalin, shingles
Pfizer has reported positive Phase III results for a new formulation of its painkiller Lyrica. In the study, a controlled-release …
Humira biosimilar released in India
December 18, 2014Research and Development, Sales and Marketing Humira, India, Zydus Cadila, anti-inflammatory, arthritis, bioscience
Indian firm Zydus Cadila has launched the first biosimilar of AbbVie’s anti-inflammatory medicine Humira, the world’s biggest-selling drug. Used as …
Government plans £6 billion precision medicine strategy
December 18, 2014Research and Development, Sales and Marketing ABPI, Cell Therapy Catapult, Ebola, George Osborne, UK, government
The government has committed to a £6 billion investment in scientific research and development as part of its science and …
Lundbeck scraps stroke drug
December 18, 2014Research and Development, Sales and Marketing AIS, DIAS, Lundbeck, acute ischemic stroke, desmoteplase, stroke
Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 …
AstraZeneca ovarian cancer drug approved in Europe
December 18, 2014Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian
The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …
Roche adds two to its board
December 18, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernard Poussot, Richard Lift, Roche, Sanofi
Roche intends to grow at its March annual general meeting via the election of Bernard Poussot and Richard Lift who …
Roche wins drug discovery award for Gazyvaro
December 18, 2014Sales and Marketing BPS, British Pharmacological Society, GSK, Gazyvaro, Roche, mekinist
Roche has been named the winner of the 2015 Drug Discover of the Year award by the British Pharmacological Society …
Janssen Healthcare Innovation two-time finalists at eyeforpharma Barcelona Awards
December 17, 2014Janssen Healthcare Innovation’s Care4Today programme is set to take two of the highest honours at the 2015 eyeforpharma Barcelona Awards …
PM Society names pharma prize finalists
December 17, 2014Medical Communications, Sales and Marketing GSK, Mundipharma, Shire, VCCP Health, digital awards, pm society
The finalists for the PM Society Awards have been announced today as pharma and med comms agencies gear up to …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
